Stock Analysts

Polycom Partners Jive (CSCO) (PLCM)

A leading provider of video and audio conferencing equipment and related network infrastructure, Polycom, Inc. ( PLCM ) recently partnered with a reputed social business solution provider, Jive Software to combine its popular HD video communication service with the latter’s other business solutions in order to provide value-added service to the Jive customers. Presently, large organizations are increasingly implementing different social interactive services like Facebook, Twitter and Youtube to enhance customer relation as well as for retaining customers […]

Stock Analysts

Cracker Beats Estimate (CBRL) (RRGB)

Cracker Barrel Old Country Store Inc . ( CBRL ) reported fourth quarter 2011 a djusted earnings of 99 cents per share, beating the Zacks Consensus Estimate of 90 cents. Quarterly earnings exclude a charge of 25 cents related to organizationa l changes and a new bank facility. […]

Mergers & Acquisitions

Cellfish Acquires Bandsintown, the Leading Live Concert Tracking and Discovery Application on Facebook

Cellfish Acquires Bandsintown, the Leading Live Concert Tracking and Discovery Application on Facebook PR Newswire NEW YORK and SAN DIEGO, Sept. 15, 2011 NEW YORK and SAN DIEGO , Sept. 15, 2011 /PRNewswire/ — Cellfish , a leading mobile and social application publisher, today announced its acquisition of Bandsintown , the #1 live concert tracking and discovery application on Facebook, and ranked in the site’s top 5 music apps by monthly average users (MAU), along with Root Music, ReverbNation, Pandora, and Vevo for Artists […]

Stock Analysts

Novo Nordisk’s Data at EASD (AMLN) (LLY) (MRK) (NVO)

Novo Nordisk ( NVO ) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who had not received any treatment before or previously received only one oral anti-diabetic drug (OAD), led to greater improvements in glycaemic control than those who had been dosed two or more OAD’s. The second trial showed that when type II diabetes patients switched from oral treatment with Merck ’s ( MRK ) Januvia to injectable Victoza (once daily) experienced increased treatment satisfaction as well as significant reductions in blood glucose and body weight […]